Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of SGLT2 Inhibitor on MAFLD in Patients With Insulin Resistance
NCT07891234Phase 4Not yet recruiting
- Start
- Oct 2026
- Primary completion
- Oct 2027
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin in metabolic dysfunction associated fatty liver disease (MAFLD). Planned start Oct 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
metabolic dysfunction associated fatty liver disease (MAFLD)
Beyond the preview
Go deeper on NCT07891234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07891234.